Intellia Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 11, 2020 / 07:45PM GMT
Martin Douglas Auster - Crédit Suisse AG - Research Division - Research Analyst

Okay. Hello, everybody. Welcome. Thanks for joining us. This is -- I'm Marty Auster. I'm the lead smid cap biotech analyst at Crédit Suisse. You are tuning in again to the 29th Annual Virtual Healthcare Conference. Right now, we're being joined by Intellia Therapeutics. I've got John Leonard, CEO with me. John, really happy to have you here. We've got a number of questions. We're hoping to kind of throw at you.

Questions and Answers:

Martin Douglas Auster - Crédit Suisse AG - Research Division - Research Analyst

Maybe if you could start with just maybe a quick introduction of Intellia and kind of a little bit about just the vision going forward.

John M. Leonard - Intellia Therapeutics, Inc. - President, CEO & Director

So thanks, Marty. Happy to be here. So Intellia is a CRISPR/Cas9-based gene editing company, and a leader in the space, and we've been active now for a few
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot